[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Clinical trial NCT05870579 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05870579
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-13
- Primary completion
- 2026-12-30
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.